Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial | Synapse
Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial
Key Points
Tenecteplase demonstrates improved outcomes in patients with basilar artery occlusion.
The trial shows a significant reduction in disability measured by the modified Rankin Scale at 90 days.
This study employs a multicentre, prospective, randomized, open-label design with blinded endpoints.
These findings may influence treatment protocols for acute basilar artery occlusion to integrate tenecteplase.